股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 FF301 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 中國匯融金融控股有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國匯融金融控股有限公司 呈交日期: 2025年12月4日 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,00 ...

Core Viewpoint - The article discusses the concept of stock pledge financing as a flexible tool for major shareholders of listed companies to access liquidity without selling their shares, thus maintaining their control over the company [1][7]. Group 1: Stock Pledge Financing Overview - Stock pledge financing allows major shareholders to use their shares as collateral to obtain funds from financial institutions, addressing immediate financial needs while preserving ownership [4][7]. - This method is likened to pawning a valuable item, where the shareholder retains the asset but risks losing it if they fail to repay the loan [4][9]. Group 2: Benefits of Stock Pledge Financing - It provides liquidity to shareholders without losing their shareholder status, enabling them to fund operations, investments, or mergers [10]. - Unlike direct stock sales, stock pledge financing does not immediately impact market perception or stock prices, helping to stabilize market confidence [11]. - The process is efficient and flexible, often featuring lower interest rates compared to traditional loans, thus quickly meeting funding needs [12]. Group 3: Stock Pledge Financing Process - The standard process begins with discussions and due diligence, where financial institutions assess the shareholder's qualifications, the purpose of the funds, and the quality of the pledged stock [13]. - Key terms such as financing scale, duration, interest rate, and pledge ratio are established in the agreement, with specific risk control measures in place [15]. - Risk control includes a pledge ratio, warning line, and liquidation line to manage potential declines in stock value and protect the lender's interests [16][17]. Group 4: Risks and Considerations - While stock pledge financing can alleviate financial pressure and support business development, excessive pledge ratios or poor management can lead to risks such as forced liquidation and control disputes [17].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國匯融金融控股有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 呈交日期: 2025年10月8日 公司名稱: 中國匯融金融控股有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | ...

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][10] Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [3][4] - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [9] - A exclusivity period is set from the signing date until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [9] Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [11][13] - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [11][13] Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [15] - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% year-on-year to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [18][19]

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [1][2]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [2]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [7]. - A exclusivity period is established from the signing date until May 31, 2026, during which the sellers cannot negotiate with other parties regarding the equity transfer [7]. Group 2: Strategic Intent - The acquisition is part of Dongxing Medical's strategic need for business development and aims to extend its surgical medical device industry chain while actively expanding into the synthetic biology field [8]. - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [8][10]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [11]. - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [13][14].

Group 1 - The core point of the article is that Dongxing Medical announced the acquisition of 90% of Wuhan Yijiaobao's shares, which will make it a subsidiary if the transaction is successfully completed [1][4]. - Dongxing Medical aims to expand its synthetic biology business segment through this acquisition, as part of its strategic business development [4]. - Wuhan Yijiaobao is identified as a high-tech enterprise focused on the research, production, and sales of advanced orthopedic and biomedical materials [4]. Group 2 - As of September 26, Dongxing Medical's stock price was 27.96 yuan per share, with a market capitalization of approximately 2.8 billion yuan [5]. - The ownership structure of Wuhan Yijiaobao is straightforward, with only two shareholders involved [5]. - Dongxing Medical has around 10,400 shareholders as of September this year [5].

CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1290） 各位非登記股東1 ： 於本公司網站登載公司通訊之通知 謹此通知 閣下，中國匯融金融控股有限公司（「本公司」）之下述公司通訊（「2 本次公司通訊」）之中、英文 版本，現已登載於本公司網站www.cnhuirong.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」） 網站www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通 訊的印刷本，本次公司通訊的印刷本已隨函附上。 1. 非登記股東指將所持有之本公司股份存放於中央結算系統的人士或公司。 2. 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括 但不限於(a)董事會報告，公司年度帳目連同核數師報告以及（如適用）財務摘要報告；(b)中期報告及（如適用）中 期摘要報告；(c)季度報告（如有）；(d)會議通告；(e)上市文件；( ...

CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1290） 各位註冊股東： 於本公司網站登載公司通訊之通知 謹此通知 閣下，中國匯融金融控股有限公司（「本公司」）之下述公司通訊（「1 本次公司通訊」）之中、英文 版本，現已登載於本公司網站www.cnhuirong.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」） 網站www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通 訊的印刷本，本次公司通訊的印刷本已隨函附上。 為了支援通過電郵進行電子通訊，本公司建議 閣下向本公司香港股份過戶登記分處卓佳證券登記有限 公司（「香港股份過戶登記分處」）（地址為香港夏慤道16號遠東金融中心17樓）發出（不少於7天的）合理書 面通知，或發送電郵至1290-ecom@vistra.com向本公司提供 閣下的電郵地址。 股東有責任提供有效的電郵地址。若 閣下沒有提供有效的電郵地址，本公司將透過 ...